

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
**WO 2004/052296 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2003/039029
- (22) International Filing Date: 8 December 2003 (08.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/431,812 9 December 2002 (09.12.2002) US
- (71) Applicants (for all designated States except US): **THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.** [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602-7411 (US). **EMORY UNIVERSITY** [US/US]; 1380 South Oxford Road, Atlanta, GA 30322 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHU, Chung, K.** [US/US]; 115 Cedar Springs Place, Athens, GA 30605 (US). **SCHINAZI, Raymond, F.** [US/US]; 1524 Regency Walk Dr., Decatur, GA 30033 (US).
- (54) Title: **DIOXOLANE THYMINE AND COMBINATIONS FOR USE AGAINST 3TC/ AZT RESISTANT STRAINS OF HIV**
- (57) Abstract: The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R<sup>1</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioxolane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R<sup>1</sup> is preferably H or a C<sub>2</sub>-C<sub>18</sub> acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.



(I)

WO 2004/052296 A2